In the manufacture of film-coated estradiol valerate tablets labeled at 1 mg or 2 mg for oral hormone replacement therapy, the formulated drug load in the compressed core is commonly held at 1.0% w/w and 2.0% w/w respectively when a 100 mg core mass is used. The API is a low-dose, poorly water-soluble steroid ester; therefore content uniformity rather than simple blend homogeneity is the primary manufacturing risk. Compliance for finished tablet testing is anchored to USP <905> Uniformity of Dosage Units, USP <711> Dissolution, and USP <701> Disintegration, with dissolution also reportable under Ph. Eur. 2.9.3; the active pharmaceutical ingredient must meet the relevant pharmacopoeial estradiol valerate monograph, and manufacturing is performed under 21 CFR 211 current good manufacturing practice. The downstream process typically begins with geometric pre-blending of estradiol valerate with lactose monohydrate or microcrystalline cellulose in a bin blender to reduce segregation risk, followed by high-shear wet granulation using an aqueous povidone solution and fluid-bed drying at inlet air temperature between 50°C and 65°C until loss on drying is not more than 2.0% w/w. Dried granules are milled through a 0.8 mm screen, lubricated with magnesium stearate at 0.5% w/w to 1.0% w/w in a V-blender, and compressed on a rotary tablet press at a main compression force between 5 kN and 15 kN; target tablet hardness is commonly 60 N to 100 N, friability is not more than 1.0%, and disintegration time is not more than 15 min. Film coating with an aqueous Opadry system adds 2% to 3% tablet weight gain. The terminal finished dosage types are film-coated round tablets packed in PVC/aluminum blister strips, primarily for continuous or cyclic estrogen monotherapy in menopausal hormone therapy.

What Limits Phase-Specific Content Uniformity in Estradiol Valerate/Norgestrel Sequential HRT Tablets?

Sequential oral hormone replacement therapy tablets use a biphasic regimen in which monocomponent estradiol valerate tablets labeled at 2 mg are followed by combination tablets containing 2 mg estradiol valerate plus 0.5 mg norgestrel. In a representative 100 mg core mass, the addition ratio is 2.0% w/w estradiol valerate in both phases and 0.5% w/w norgestrel in the combination phase. The progestogen load is deliberately small; therefore norgestrel content uniformity carries the same segregation risk as the estrogen component. The downstream process uses two distinct granulation campaigns with separate bins and transfer lines to prevent cross-phase contamination. Compression is performed first for the estrogen-only tablets, followed by the combination tablets only after line clearance has been documented. Cleaning validation under 21 CFR 211.67 must demonstrate residual norgestrel carryover below a health-based exposure limit derived from the subsequent product. In-process controls include average mass, tablet hardness, friability, disintegration, and individual drug content by validated HPLC for both phases. The terminal finished dosage type is a biphasic calendar pack containing 11 estrogen-only tablets and 10 combination tablets, followed by 7 tablet-free days; packaging and labeling controls under 21 CFR 211.125 are critical because the two phases must remain distinguishable by color and sequential position throughout shelf life.

When Four Strengths Share One Film-Coating Line: Estradiol Valerate/Dienogest Multiphasic Tablets

Multiphasic oral contraceptive tablets based on estradiol valerate and dienogest are manufactured as four active strengths arranged in a 28-day cycle. In a representative approved sequence, the estrogen content decreases from 3 mg to 2 mg to 1 mg, while dienogest appears at 2 mg and 3 mg in the combination phase. The addition ratio in the compressed core therefore ranges from approximately 1.0% w/w to 3.0% w/w for estradiol valerate and from 2.0% w/w to 3.0% w/w for dienogest when a 100 mg core mass is used. Manufacturing requires four or five distinct granulations; each is produced by wet granulation, dried, milled, and compressed sequentially. The shared compression and film-coating line creates a process conflict because carryover from a 3 mg phase into a 1 mg phase can exceed content uniformity acceptance limits if cleaning is inadequate. Segregation risk is managed by batch-size justification, passivated contact surfaces, and in-process blend RSD control at ≤ 5.0%. After compression, phase-specific color coating is applied; color separation is verified against approved coating standards. The terminal finished dosage type is a 28-tablet calendar blister containing 2 estrogen-only tablets, 5 low-progestogen combination tablets, 17 high-progestogen combination tablets, 2 estrogen-only step-down tablets, and 2 inert tablets. Finished product testing includes USP <905>, USP <711>, and degradation products by validated stability-indicating HPLC.

Oily Depot Vehicle Rheology and Sterile Filtration for 10–40 mg/mL Intramuscular Estradiol Valerate

Intramuscular estradiol valerate injection is formulated as a sterile oily solution at strengths of 10 mg/mL, 20 mg/mL, and 40 mg/mL; the active pharmaceutical ingredient is dissolved in refined sesame oil or a similar fixed oil, with preservative and co-solvent levels matched to single-dose or multi-dose container configuration. The production process requires heating the fixed oil to 40°C to 50°C to dissolve estradiol valerate under nitrogen protection, followed by filtration through a 0.45 µm pre-filter and then through a sterilizing-grade 0.22 µm membrane compatible with viscous oily vehicles. Because the oil increases viscosity and reduces filtration flux, filter integrity testing is performed before and after use, and the fill is conducted aseptically in an EU GMP Annex 1 grade A zone. Terminal steam sterilization of this product configuration is not routinely validated because the ester in an oily depot may degrade under standard aqueous sterilization cycles; published data for this specific configuration is limited, and any terminal sterilization claim requires cycle development on the finished formulation. Release testing includes sterility per USP <71> or Ph. Eur. 2.6.1, bacterial endotoxins per USP <85> or Ph. Eur. 2.6.14, and particulate matter per USP <788>. The terminal finished dosage types are single-dose ampoules or multi-dose vials for deep intramuscular injection; the oily depot releases estradiol valerate by hydrolysis to estradiol and provides systemic dosing at intervals of approximately 3 to 4 weeks when clinically indicated.

Compounded nonsterile oral capsules and powder-in-bottle granules containing estradiol valerate are prepared in licensed pharmacy settings for patient-specific dosing where commercially available tablets cannot be split or where a prescribed strength is unavailable. The addition ratio in these preparations is typically 0.5 mg, 1 mg, or 2 mg estradiol valerate per capsule or sachet, with a total powder fill weight of 100 mg to 200 mg; lactose monohydrate is the most common diluent. The downstream process relies on geometric trituration of the API with a lactose pre-blend using a mortar and pestle or a pharmacy-scale V-blender, followed by semi-automatic capsule filling and weight-variation assessment. For oral granules, a wet mass is prepared with ethanol or purified water, passed through a 10-mesh stainless steel screen, and dried at not more than 40°C; the dried granules are then packed into single-dose sachets. Compliance is anchored to USP <795> for nonsterile compounding, with outsourcing facilities also subject to 21 CFR 210 and 211 when registered under Section 503B. Because no harmonized finished capsule monograph exists for this specific estradiol valerate configuration, batch-specific chemical stability data and beyond-use dating must be generated from the compounding record. The terminal finished dosage types are hard gelatin capsules, oral granules in unit-dose sachets, and powder-in-bottle preparations for reconstitution.